A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention).

Trial Profile

A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention).

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Insulin glargine (Primary) ; Omega-3-acid ethyl esters (Primary)
  • Indications Cardiovascular disorders; Glucose intolerance; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ORIGIN; ORIGIN-GRACE; ORIGINALE
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Jun 2017 Results assessing novel biomarkers predicting heart failure hospitalization using stored serum sample from ORIGIN participants (n=8018), presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 01 Apr 2017 Preliminary results of the DEVOTE trial and its comparison with respect to the ORIGIN trial, published in the Diabetes Therapy
    • 19 May 2016 Results of a retrospective analysis on Cardiovascular Outcomes of EMPA-REG, PROactive, ORIGIN, SAVOR, EXAMINE, CANVAS, ELIXA, TECOS, LEADER studies, published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top